Czechia· CZ-0255592
XOFLUZA
A baloxavir marboxil product containing baloxavir marboxil, registered in Czechia by Roche Registration GmbH, Grenzach-Wyhlen. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Baloxavir marboxil is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AX25 (baloxavir marboxil), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Baloxavir marboxil · ATC J05AX25
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- BALOXAVIR MARBOXIL
- Manufacturer
- Roche Registration GmbH, Grenzach-Wyhlen
- Country
- Czechia (CZ)
- ATC code
- J05AX25
- ATC class
- Baloxavir marboxil
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
40 interactions on record for baloxavir marboxil.
Graded by severity as the source publishes them — 40 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Baloxavir marboxil · interactions on record
40 records
- 40 moderate
Most severe, free to view
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Magnesium hydroxideA02AA04moderate
- Kombinationen von AluminiumsalzenA02AB10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Baloxavir marboxil in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandXofluza 40 mg, FilmtablettenRoche Pharma (Schweiz) AG
- SpainXOFLUZA 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULARoche Registration Gmbh
- FinlandXofluzaRoche Registration GmbH
- IrelandXofluza 40 mg film-coated tabletsRoche Registration GmbH
- IcelandXofluzaRoche Registration GmbH*
- NetherlandsXofluza 40 mg, filmomhulde tablettenRoche Registration GmbH
- PolandXofluzaRoche Registration GmbH
- SwedenXofluza 40 mg Filmdragerad tablettRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xofluza
- Liechtenstein · Xofluza
- Norway · Xofluza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0a03112c-7752-42e1-8395-c81a37bcf50f GET /v1/drugs/0a03112c-7752-42e1-8395-c81a37bcf50f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "40MG",
"pack_size": "1",
"substance": "BALOXAVIR MARBOXIL",
"cz_kod_sukl": "0255592",
"product_type": "CH",
"substance_codes": "21312",
"registration_state": "R",
"registration_number": "EU/1/20/1500/004"
}See everything about baloxavir marboxil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.